Abstract Number: 0374 • ACR Convergence 2025
Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
Background/Purpose: Vaccine-preventable diseases pose greater risk to children with rheumatic diseases treated with immunosuppressive therapies and to those with underlying immune dysregulation. Despite the importance…Abstract Number: 1419 • ACR Convergence 2025
Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) is a relatively new disease concept. We developed an educational program to promote early and appropriate referral to specialists based…Abstract Number: 2216 • ACR Convergence 2025
Expanding Reproductive Health Assessments in Rheumatic Diseases: A Comparative Analysis of Demographic and Disease-Specific Factors
Background/Purpose: Building on our 2024 ACR study (Topalsky et al.) that described broad knowledge gaps and interest in reproductive health education among women with rheumatic…Abstract Number: 0375 • ACR Convergence 2025
Association of Glucocorticoid Toxicity Index Scores with Quality-of-Life and Healthcare Resource Utilization at 6 Months in a Real-World Cohort of Individuals Receiving Glucocorticoids
Background/Purpose: Glucocorticoids (GCs) are used long-term by approximately 1% of the adult population and contribute to excess morbidity and mortality. We prospectively assessed Glucocorticoid Toxicity…Abstract Number: 1915 • ACR Convergence 2025
Innovative Clinical Trial Recruitment Approaches in Lupus Research: LuCIN Site Perspectives on Use of Social Media and Artificial Intelligence
Background/Purpose: Lupus disproportionately impacts racial and ethnic minorities, yet these groups remain underrepresented in clinical trials. Lupus Therapeutics, overseeing the Lupus Clinical Investigators Network (LuCIN),…Abstract Number: 2318 • ACR Convergence 2025
Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
Background/Purpose: There is a dearth of literature exploring challenges faced by rheumatologists in the referral, diagnosis, management, and monitoring of patients with suspected axial spondyloarthritis…Abstract Number: 0738 • ACR Convergence 2025
Real World Steroid Burden, Treatment Patterns, and Rheumatologists’ Perceptions on Advanced Therapy in Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in patients 50 years and older. Glucocorticoids (GC) are the mainstay of treatment for GCA…Abstract Number: 1923 • ACR Convergence 2025
A Real-World Survey On Physicians’ Perspectives Of Uncontrolled Gout And Gout Management Practices.
Background/Purpose: Managing uncontrolled gout (UG) can involve a multi-disciplinary approach involving physicians of different specialities, all of whom may have differing perspectives or approaches for…Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…Abstract Number: 0600 • ACR Convergence 2025
Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region
Background/Purpose: Difficult-to-treat systemic lupus erythematosus (D2T-SLE) presents a major challenge due to disease heterogeneity and a lack of unified classification. While the D2T concept has…Abstract Number: 1973 • ACR Convergence 2025
Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic
Background/Purpose: Existing data demonstrate that clinical pharmacist integration in rheumatology clinics improves provider satisfaction, patient outcomes, medication adherence, and RAPID-3 (Routine Assessment of Patient Index…Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…Abstract Number: 0602 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…Abstract Number: 2031 • ACR Convergence 2025
Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
Background/Purpose: Interstitial lung disease (ILD) is common and important feature of systemic autoimmune rheumatic diseases (SARD). Rheumatologists and pulmonologists are central to the care of…Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
- 1
- 2
- 3
- …
- 14
- Next Page »